Brigham and Women's Hospital

Charles Lee of The Jackson Laboratory inducted as a fellow of The Korean Academy of Science and Technology

Retrieved on: 
Jeudi, décembre 14, 2023
Genetic distance, AAAS, Genetics, Research, Jackson Laboratory, FACMG, Disease, KAST, Genomics, Ho-Am Prize in Science, HUGO, JAX, Faculty, Human Genome Organisation, Health, DSM-IV codes, Genome, Harvard Medical School, Natural science, Brigham and Women's Hospital, Biology, AACR, Hospital, Lee, Pharmaceutical industry, Medicine

FARMINGTON, Conn., Dec. 14, 2023 /PRNewswire/ -- The Korean Academy of Science and Technology (KAST), the highest institution of its kind in South Korea, announced Charles Lee, Ph.D., FACMG , as a newly inducted fellow of the Academy.

Key Points: 
  • FARMINGTON, Conn., Dec. 14, 2023 /PRNewswire/ -- The Korean Academy of Science and Technology (KAST), the highest institution of its kind in South Korea, announced Charles Lee, Ph.D., FACMG , as a newly inducted fellow of the Academy.
  • Lee is the scientific director and professor at The Jackson Laboratory for Genomic Medicine, and is the Robert Alvine Family Endowed Chair.
  • "I am profoundly honored to join so many inspirational scientists and colleagues who are members of the Korean Academy of Science and Technology, and am deeply grateful for this tremendous opportunity," says Lee.
  • Dr. Lee is also responsible for the scientific direction and coordination of The Jackson Laboratory (JAX) for Genomic Medicine.

Thomas Jefferson University Names Said Ibrahim, MD, MBA, MPH the Anthony F. and Gertrude M. DePalma Dean of Sidney Kimmel Medical College

Retrieved on: 
Jeudi, décembre 14, 2023
Health equity, Interim, National academy, Teaching hospital, Patient, MBA, School of Public Health, Medical college, Doctor of Philosophy, Bangladesh Technical Education Board, School, Internal medicine, JUP, Thomas Jefferson University, Division, North Shore University Hospital, Northwell Health, Health, Harvard Medical School, Knee, Public health, Innovation, Physician, Harvard University, Weill Cornell Medicine, Student, Mentorship, University, Diversity, Master, Education, Jefferson Health, Research, Bachelor, National Academy of Medicine, Faculty, Inclusion, Business administration, NIH, MD, MPH, Brigham and Women's Hospital, Hospital, Nursing, Medicine, Veteran

PHILADELPHIA, Dec. 14, 2023 /PRNewswire/ -- On December 1, Jefferson welcomed newly appointed Anthony F. and Gertrude M. DePalma Dean of Thomas Jefferson University's esteemed Sidney Kimmel Medical College and president of Jefferson University Physicians (JUP), Said Ibrahim, MD, MBA, MPH. Dr. Ibrahim is an internal medicine physician who has served as a primary care doctor, educator, administrator, and clinician investigator, brings a wealth of higher education, research and healthcare experience to this crucial leadership role, and is nationally recognized for his efforts to combat health disparities.

Key Points: 
  • PHILADELPHIA, Dec. 14, 2023 /PRNewswire/ -- On December 1, Jefferson welcomed newly appointed Anthony F. and Gertrude M. DePalma Dean of Thomas Jefferson University's esteemed Sidney Kimmel Medical College and president of Jefferson University Physicians (JUP), Said Ibrahim, MD, MBA, MPH.
  • "Dr. Ibrahim has demonstrated a strong commitment to fostering innovation, collaboration and inclusivity within the medical community," said Susan Aldridge, PhD, Interim President of Thomas Jefferson University.
  • As Dean, Dr. Ibrahim will build upon the existing collaborative, transdisciplinary, and vibrant culture to further position the Sidney Kimmel Medical College and Jefferson Health as a premier academic healthcare institution in Philadelphia and beyond.
  • Dr. Ibrahim received his Bachelor's degree from Oberlin College and his Medical degree from Case Western Reserve University School of Medicine.

The Inner Circle Acknowledges, Douglas R. Adams as a Pinnacle Lifetime Member for his contributions to the field of Orthopedic Surgery

Retrieved on: 
Lundi, décembre 4, 2023
Inner circle, Orthopedic surgery, Air force, Human, Avascular necrosis, Hospital, Love, Birth, Surgeon, Ankle, Infection, Madigan Army Medical Center, Trust, Fracture, Tears, Neoplasm, AC, Army, Minimus, ABOS, University, Medical degree, Trauma, Knee, Massachusetts General Hospital, Sports medicine, Lieutenant, Brigham and Women's Hospital, Education, Dentistry, Nursing, Medicine

COLORADO SPRINGS, Colo., Dec. 4, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Douglas R. Adams is acknowledged as a Pinnacle Lifetime Member for his contributions to the field of Orthopedic Surgery.

Key Points: 
  • COLORADO SPRINGS, Colo., Dec. 4, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Douglas R. Adams is acknowledged as a Pinnacle Lifetime Member for his contributions to the field of Orthopedic Surgery.
  • A highly respected orthopedic surgeon, Dr. Adams is affiliated with Colorado Orthopedic Specialists, a part of the HealthONE Physician Group.
  • He is a specialist in hip arthroscopy and hip preservation surgery; sports medicine and arthroscopic surgery; and robotic total joint replacement surgery.
  • Dr. Adams noted that orthopedic surgery is a specialized branch of surgery focused on conditions related to the musculoskeletal system.

MIT Technology Review's flagship event, EmTech MIT, begins next week on the MIT campus

Retrieved on: 
Jeudi, novembre 9, 2023
Online, MIT Technology Review, Research, MIT, Q&A, Brigham and Women's Hospital, Artificial Intelligence Laboratory, Life, MIT Computer Science and Artificial Intelligence Laboratory, CSAIL, Emtech, Business, JPMorgan Chase, OpenAI, Redwood Materials, Inc., AI, IBM, Hospital, Wellness, Frontiers, Climate change, Computer science, Medical device, Information technology, Online shopping

CAMBRIDGE, Mass., Nov. 9, 2023 /PRNewswire/ -- EmTech MIT, MIT Technology Review's flagship event on emerging technology and global trends, opens next week in-person and online from November 14-15, 2023, promising two days of innovation and inspiration for industry leaders, researchers, and innovators.

Key Points: 
  • As AI, biotech, and climate change continue to dominate the public consciousness and as more people look to understand what the future might look like, the questions and solutions discussed at EmTech MIT are more relevant than ever.
  • Curated by the MIT Technology Review editorial team and backed by the technology expertise of MIT, EmTech MIT speaks to this legacy and looks ahead to the real-world applications and commercial and social impact of the technologies and solutions explored onstage.
  • Attendees experience MIT Technology Review's journalism brought to life with thought-provoking interviews and Q&A sessions and unparalleled opportunities to connect with industry experts on the MIT campus.
  • The virtual experience includes an interactive event hub featuring livestreamed sessions, videos on-demand, and networking opportunities.

Recor Medical and Otsuka Medical Devices Announce First FDA-Approved Renal Denervation System for the Treatment of Hypertension

Retrieved on: 
Mercredi, novembre 8, 2023
JAMA, FDA, Harvard Medical School, Brigham and Women's Hospital, Food, American Medical Association, Blood pressure, Physician, Mortality, MD, Disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Journal, Hypertension, Division, Treatments for overactive bladder, Diabetes, RDN, Patient, Hospital, Associate, Pharmaceutical industry, ReCore, Endocrinology, Medicine

PALO ALTO, Calif., Nov. 8, 2023 /PRNewswire/ -- Recor Medical, Inc. ("Recor") and its parent company, Otsuka Medical Devices Co., Ltd. ("Otsuka Medical Devices") today announced the U.S. Food and Drug Administration (FDA) has approved Recor's Paradise™ Ultrasound Renal Denervation (RDN) system for the treatment of hypertension.

Key Points: 
  • Approval of the Paradise™ Ultrasound Renal Denervation system makes innovative hypertension treatment available for the first time in the U.S.
    PALO ALTO, Calif., Nov. 8, 2023 /PRNewswire/ -- Recor Medical, Inc. ("Recor") and its parent company, Otsuka Medical Devices Co., Ltd. ("Otsuka Medical Devices") today announced the U.S. Food and Drug Administration (FDA) has approved Recor's Paradise™ Ultrasound Renal Denervation (RDN) system for the treatment of hypertension.
  • The Paradise system is intended as an adjunctive treatment option when lifestyle changes and medications have not adequately controlled a patient's blood pressure.
  • The Paradise catheter features the exclusive HydroCooling™ system, which circulates sterile water through the balloon catheter during the procedure to help protect the renal artery wall.
  • Recor has been focused on developing and testing the Paradise Ultrasound RDN system for the treatment of hypertension since 2009.

Recor Medical and Otsuka Medical Devices Announce First FDA-Approved Renal Denervation System for the Treatment of Hypertension

Retrieved on: 
Mercredi, novembre 8, 2023
JAMA, FDA, Harvard Medical School, Brigham and Women's Hospital, Food, American Medical Association, Blood pressure, Physician, Mortality, MD, Disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Journal, Hypertension, Division, Treatments for overactive bladder, Diabetes, RDN, Patient, Hospital, Associate, Pharmaceutical industry, ReCore, Endocrinology, Medicine

PALO ALTO, Calif., Nov. 8, 2023 /PRNewswire/ -- Recor Medical, Inc. ("Recor") and its parent company, Otsuka Medical Devices Co., Ltd. ("Otsuka Medical Devices") today announced the U.S. Food and Drug Administration (FDA) has approved Recor's Paradise™ Ultrasound Renal Denervation (RDN) system for the treatment of hypertension.

Key Points: 
  • Approval of the Paradise™ Ultrasound Renal Denervation system makes innovative hypertension treatment available for the first time in the U.S.
    PALO ALTO, Calif., Nov. 8, 2023 /PRNewswire/ -- Recor Medical, Inc. ("Recor") and its parent company, Otsuka Medical Devices Co., Ltd. ("Otsuka Medical Devices") today announced the U.S. Food and Drug Administration (FDA) has approved Recor's Paradise™ Ultrasound Renal Denervation (RDN) system for the treatment of hypertension.
  • The Paradise system is intended as an adjunctive treatment option when lifestyle changes and medications have not adequately controlled a patient's blood pressure.
  • The Paradise catheter features the exclusive HydroCooling™ system, which circulates sterile water through the balloon catheter during the procedure to help protect the renal artery wall.
  • Recor has been focused on developing and testing the Paradise Ultrasound RDN system for the treatment of hypertension since 2009.

First in the U.S! Palliative Care VR Educational Material by Jolly Good and Emergency Medicine Specialists

Retrieved on: 
Lundi, novembre 6, 2023
National Institute on Aging, A Jolly Good Fellow (novel), VR, Harvard Medical School, Brigham and Women's Hospital, Ageing, MPH, Terminal, Department of Medicine – University of Pamplona, GSA, Palliative care, Harvard University, Gerontological Society of America, ED, Quality of life, Caregiver, Student, Apple, Bangladesh Technical Education Board, Eye, Patient, Hospital, Communication, Associate, Emergency medicine, Nursing, MD

TOKYO, Nov. 6, 2023 /PRNewswire/ -- Jolly Good US Inc. (Brookline, Massachusetts, USA CEO: Kensuke Joji), a developer of medical VR, is pleased to announce that it has developed the first "Palliative Care Communication (*1) Training VR" in the United States in collaboration with Brigham and Women's Hospital, a Harvard affiliated hospital. In addition, using this VR, we will hold a medical VR seminar at "GSA2023", Gerontological Society of America.

Key Points: 
  • In addition, using this VR, we will hold a medical VR seminar at "GSA2023", Gerontological Society of America.
  • Therefore, Jolly Good US Inc. decided to jointly develop this product because we believe that training medical professionals on communication in palliative care by using VR, they can efficiently and effectively acquire communication skills.
  • He will give a lecture on training assessment skills, a basic skill for palliative care by using the jointly developed VR.
  • Unfortunately, opportunities to learn this palliative care communication skill are rare for non-palliative care clinicians due to training personnel, time, and cost.

TruDiagnostic Announces a New Multi-Omic Informed Biological Aging Clock that Outperforms Previous Age Calculating Methods

Retrieved on: 
Jeudi, octobre 26, 2023
EBP, Ageing, Brigham and Women's Hospital, Notifiable disease, Biomarker, Mortality, Conditional sentence, Doctor of Philosophy, Research, Protein, BioRxiv, Methylation, Risk, DNA methylation, Triglyceride, Gene, Algorithm, Hospital, Death, DNA, Dietary supplement, Medical imaging

Epigenetics (or the way our genes are put into use throughout our bodies) has emerged as a measure to evaluate aging through the development of aging 'clocks'.

Key Points: 
  • Epigenetics (or the way our genes are put into use throughout our bodies) has emerged as a measure to evaluate aging through the development of aging 'clocks'.
  • While previous DNA methylation clocks have estimated the degree of aging in an individual, they haven't been able to explain why someone might have accelerated or decelerated aging outcomes.
  • "In our research, we set out to create a first-in-class approach to quantify the biological aging process.
  • It also provides more understanding of what individual factors and biological processes are contributing to an individual's current biological age," says Dr. Lasky-Su.

Oncternal Therapeutics Adds Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board

Retrieved on: 
Mercredi, octobre 25, 2023
Trial of the century, Harvard Medical School, Brigham and Women's Hospital, Therapy, Clinical Cancer Research, Prostate cancer, MD, Dana–Farber Cancer Institute, Doctor of Philosophy, HIV disease progression rates, Journal, Internal medicine, Estate (law), Duke University School of Medicine, Abiraterone acetate, Metastasis, SAN, Oncology, Biochemistry, Massachusetts Institute of Technology, Journal of Clinical Oncology, AR, Canisius College, Patient, Hospital, SAB, Massachusetts Institute of Technology School of Engineering, Prostate, The New England Journal of Medicine, Pharmaceutical industry, Medicine, Lancet

SAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the addition of Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board (SAB).

Key Points: 
  • SAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the addition of Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board (SAB).
  • “We wholeheartedly welcome Dr. Smith to Oncternal’s Prostate Cancer Scientific Advisory Board,” said James Breitmeyer, M.D., Ph.D., Oncternal’s President and CEO.
  • He has published extensively on the treatment and prevention of bone metastases, prostate cancer survivorship, and novel androgen receptor pathway inhibitors.
  • He completed a fellowship in Medical Oncology at Dana Farber Cancer Institute and a postdoctoral fellowship at Massachusetts Institute of Technology.

Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board

Retrieved on: 
Lundi, octobre 23, 2023
American Cancer Society, Harvard–MIT Program in Health Sciences and Technology, Bachelor of Arts, Harvard Medical School, Brigham and Women's Hospital, IMGN, Genzyme, Biotechnology, ImmunoGen, MD, Drug, Harvard College, Senior, Medicine, Synageva, CBAB, ACS, LSE, Cancer, Hospital, BPMC, SAN, Management, Glycomimetic

SAN JOSE, Calif., Oct. 23, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has appointed Mark A. Goldberg, MD, to its Cancer Business Advisory Board (CBAB).

Key Points: 
  • SAN JOSE, Calif., Oct. 23, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has appointed Mark A. Goldberg, MD, to its Cancer Business Advisory Board (CBAB).
  • "We are pleased to welcome Dr. Goldberg as the 9th independent member of our CBAB," said Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences.
  • "Mark brings valuable clinical expertise in oncology, and his extensive biotechnology executive experience will be an asset to Anixa.
  • Dr. Goldberg received his Bachelor of Arts degree from Harvard College and his medical degree from the Harvard-MIT Program in Health Sciences and Technology.